| Objective:To observe the clinical efficacy of xialongpingxuan Decoction in the treatment of posterior circulation ischemia(PCI)vertigo caused by wind phlegm disturbance,and enrich the theory of this disease.Methods:The inpatients in the first Department of encephalopathy of Qinhuangdao Hospital of Traditional Chinese Medicine from February2021 to October 2021 were stochasticly splited into 34 cases in the control group and 34 cases in the treatment group in ascending order of the random number table.The control group was treated with basic treatment plus betastatin mesylate tablets,6mg,3 times a day,was taken after meals for observation.The treatment group was treated with basic treatment plus oral Chinese medicine xialongpingxuan decoction,one dose a day,twice,and took it gently for half an hour in the morning and evening.The clinical study was observed for 2 weeks.The clinical efficacy differences between the two groups were judged by comparing the scores of dizziness Rating Scale(DARS),dizziness Disorder Inventory(DHI),TCM syndrome score and TCM syndrome efficacy before and after treatment.The patients were followed up for 2 weeks after 2 weeks of clinical treatment.The data results were analyzed by SPSS25.0 for statistical analysis.Results: Results:(1)general data analysis: the gender,age,course of disease and combined basic diseases of the two groups were analyzed before treatment.No significant difference in general data(P>0.05)was found,and the two groups were comparable.(2)Vertigo Rating Scale(DARS)score: There was no significant difference between the two groups pre-treatment(P>0.05).The comparison of DARS scores pretherapy and post-treatment between them was statistically significant(P<0.01).Moreover,the DARS score in the treatment group was superior to the control group,which was statistical significant(P<0.05);(3)Vertigo disorder scale(DHI)score: The DHI scores of the first two treatment groups were not significant(P>0.05)and were comparable.After treatment,the DHI score of the two groups was contrast with that before treatment.This scale score was found to be subordinate to the pre-treatment scor.Differences were significant before and after experiment(P < 0.01),and the score reduction of the treatment group was the effect of a prior that of the control group(P<0.01);(4)TCM syndrome score: The TCM syndrome scores of the first two treatment groups were not significant(P>0.05)and were comparable.In comparison with that before treatment,the TCM syndrome score of the two groups go or come down after treatment.Differences were significant before and after experiment(P< 0.05),and the respiratory infection of TCM syndrome in the treatment group can be a carricer for the control group.Difference is significant in statistics(P< 0.05);(5)Analysis of curative effect of TCM syndrome: the effective rate of the control group was 76.5%,and that of the treatment group was 91.2%.Given all these dates,it is the difference between the two groups that has significant(P<0.05).(6)Safety analysis: no adverse reaction events occurred in the two groups during the study,and there was no abnormality in the laboratory safety index pretherapy and post-treatment;Conclusion: xialongpingxuan decoction can improve the clinical symptoms of TCM in patients with posterior circulation ischemic vertigo of wind phlegm disturbance type,and has a clear effect on reducing the degree of vertigo and improving the physical and psychological disorders of vertigo patients.No adverse reactions were found in the process of treatment and follow-up,and the effect of oral xialongpingxuan decoction is more significant than that of Western medicine alone,so it is worthy of further clinical application. |
